StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)

StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Down 19.2 %

Shares of Pulmatrix stock opened at $5.43 on Monday. The stock has a market capitalization of $19.82 million, a P/E ratio of -2.06 and a beta of 0.99. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $8.44. The company has a 50-day simple moving average of $2.41 and a 200 day simple moving average of $2.16.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.